Search Results - amy+newman

5 Results

Sort By:

Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use

Abstract: Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially...

Published: 4/8/2024 | Inventor(s): Amy Newman, Alessandro Bonifazi, Francisco Battiti, Sophe Cemaj

Keywords(s): D3R agonists, Dopamine, Newman, Parkinson’s Disease, Restless Legs Syndrome, RLS, small molecule

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology

Analogues of Modafinil for treating sleep and attention disorders

Abstract: Modafinil has attracted attention for the treatment of cognitive dysfunction in disorders such as attention-deficit/hyperactivity disorder (ADHD) as well as cocaine and methamphetamine dependence. However, modafinil has relatively low affinity for binding to the dopamine transporter (DAT) to block dopamine reuptake, and is water-insoluble,...

Published: 4/8/2024 | Inventor(s): Amy Newman, Oluyomi Okunola-Bakare, Jianjing Cao

Keywords(s): attention deficit/hyperactivity disorder (ADHD), dopamine (DAT), Modafinil, Narcolepsy, norepinephrine (NET), serotonin (SERT)

Category(s): Application > Therapeutics, Collaboration Sought > Licensing

Methods of making and using dopamine receptor selective antagonists/partial agonists

Abstract: Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse. Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors. The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use...

Published: 4/8/2024 | Inventor(s): Amy Newman, Vivek Kumar, Anverbasha Shaik

Keywords(s): Bipolar Disorder, Cannabis, DEPENDENCE, dopamine D3 receptor, drug addiction, oxycodone, SCHIZOPHRENIA

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Therapeutics

Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof

Abstract: Substance use disorder is a chronic medical condition, taking its toll on our public health care and judicial systems in an economically unsustainable way. More than 20 million Americans suffer from substance use disorders. Certainly, the development of prevention and treatment options as alternatives to incarceration is the appropriate and...

Published: 4/8/2024 | Inventor(s): Amy Newman, JoLynn Giancola, Rachel Slack, Jianjing Cao

Keywords(s): ADHD, dopamine reuptake inhibitor, Newman, sleep disorders, Substance use disorder

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Neurology

Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders

Abstract: The National Institute on Drug Abuse's Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands. The dopamine D3 receptor subtype is a member of the dopamine...

Published: 4/8/2024 | Inventor(s): Amy Newman, Peter Grundt, Jianjing Cao, Robert Luedtke, George Cyriac

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Gastroenterology, Collaboration Sought > Licensing